A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Yangxin Dingji Capsules in Preventing Recurrence after Radiofrequency Catheter Ablation for Atrial Fibrillation

INTERVENTION: Treatment group:guideline‐directed anticoagulant and anti‐arrhythmic drug therapy plus oral Yangxin Dingji Capsules,6 capsules twice daily for 3 months;Control group:guideline‐directed anticoagulant and anti‐arrhythmic drug therapy plus oral placebo,6 capsules twice daily for 3 months; CONDITION: Atrial Fibrillation BC81.3 PRIMARY OUTCOME: 1‐year atrial fibrillation progression rate; SECONDARY OUTCOME: Atrial fibrillation episode frequency and duration;Atrial fibrillation load;LAAPD,LAVI,LVEF;NT‐proBNP; Atrial Fibrillation Effect on QualiTy‐of‐life ;Score of CHA2DS2‐VASc‐60 and HAS‐BLED ;TCM syndrome score;major adverse cardiovas‐cular and cerebrovascular events; INCLUSION CRITERIA: (1)Aged 18–75 years, both sexes eligible; (2) Meets diagnostic criteria for recurrence after radiofrequency catheter ablation (RFCA) for atrial fibrillation, with recurrence occurring 3 months to 1 year following a single RFCA procedure; (3) Meets diagnostic criteria for the TCM pattern "palpitations due to qi and yin deficiency"; (4) No plan to undergo repeat cardiac RFCA; (5) Voluntary participation with signed informed consent.